HK1143523A1 - Engineered anti-alpha v-integrin hybrid antibodies v- - Google Patents
Engineered anti-alpha v-integrin hybrid antibodies v-Info
- Publication number
- HK1143523A1 HK1143523A1 HK10109278.2A HK10109278A HK1143523A1 HK 1143523 A1 HK1143523 A1 HK 1143523A1 HK 10109278 A HK10109278 A HK 10109278A HK 1143523 A1 HK1143523 A1 HK 1143523A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- alpha
- hybrid antibodies
- engineered anti
- integrin hybrid
- integrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07013964 | 2007-07-17 | ||
| PCT/EP2008/005852 WO2009010290A2 (fr) | 2007-07-17 | 2008-07-17 | Anticorps hybrides modifiés dirigés contre l'intégrine alpha v |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1143523A1 true HK1143523A1 (en) | 2011-01-07 |
Family
ID=40029330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10109278.2A HK1143523A1 (en) | 2007-07-17 | 2010-09-28 | Engineered anti-alpha v-integrin hybrid antibodies v- |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8562986B2 (fr) |
| EP (2) | EP2526967A1 (fr) |
| JP (1) | JP5341889B2 (fr) |
| KR (1) | KR101559596B1 (fr) |
| CN (1) | CN101687039B (fr) |
| AU (1) | AU2008277907B2 (fr) |
| BR (1) | BRPI0815567B8 (fr) |
| CA (1) | CA2693863C (fr) |
| CY (1) | CY1113493T1 (fr) |
| DK (1) | DK2167128T3 (fr) |
| EA (1) | EA019485B1 (fr) |
| ES (1) | ES2395799T3 (fr) |
| HK (1) | HK1143523A1 (fr) |
| HR (1) | HRP20120949T1 (fr) |
| IL (1) | IL203269A (fr) |
| PL (1) | PL2167128T3 (fr) |
| PT (1) | PT2167128E (fr) |
| SI (1) | SI2167128T1 (fr) |
| WO (1) | WO2009010290A2 (fr) |
| ZA (1) | ZA201001124B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2747937C (fr) | 2008-12-23 | 2019-02-26 | Merck Patent Gmbh | Biomarqueurs pour inhibiteurs ayant une activite antiangiogenique |
| SG178348A1 (en) * | 2009-08-19 | 2012-03-29 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
| PL2672994T3 (pl) | 2011-02-11 | 2018-11-30 | Merck Patent Gmbh | Przeciwciało przeciwko integrynie alfa-v do leczenia raka prostaty |
| AU2014318017B2 (en) * | 2013-09-05 | 2020-02-06 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| BR112017005336A2 (pt) * | 2014-09-17 | 2017-12-12 | Merck Patent Gmbh | método de tratamento de cânceres sólidos e/ou metástases dos mesmos, medicamentos com essa finalidade e método para prever o resultado clínico de tratamento de cânceres sólidos e/ou metástases dos mesmos |
| AU2015317411A1 (en) | 2014-09-17 | 2017-04-27 | Merck Patent Gmbh | A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases |
| SG11201703192SA (en) | 2014-11-21 | 2017-05-30 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| CN107250157B (zh) | 2014-11-21 | 2021-06-29 | 百时美施贵宝公司 | 包含修饰的重链恒定区的抗体 |
| JP7034914B2 (ja) | 2015-11-23 | 2022-03-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体 |
| WO2017088974A2 (fr) * | 2015-11-23 | 2017-06-01 | Merck Patent Gmbh | Anticorps de l'intégrine anti-alpha-v pour le traitement de la fibrose et/ou de troubles fibrotiques |
| EP3510407A1 (fr) | 2016-09-08 | 2019-07-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de diagnostic et de traitement du syndrome néphrotique |
| EP3551046B1 (fr) | 2016-12-07 | 2023-07-19 | Biora Therapeutics, Inc. | Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal |
| TW201834710A (zh) | 2016-12-14 | 2018-10-01 | 美商寶珍那提公司 | 以整合素抑制劑治療胃腸道疾病 |
| WO2018141894A1 (fr) | 2017-02-02 | 2018-08-09 | Merck Patent Gmbh | Appariement préféré de domaines d'anticorps |
| CN108948206B (zh) * | 2017-05-23 | 2022-08-23 | 赵磊 | 一种抗egfr/pd-1双靶向抗体、其制备方法及用途 |
| CN111683963B (zh) | 2017-10-03 | 2024-03-29 | 默克专利有限公司 | 半胱氨酸工程化的抗原结合分子 |
| WO2019089544A1 (fr) * | 2017-11-01 | 2019-05-09 | Tufts Medical Center, Inc. | Constructions d'anticorps bispécifiques et procédés d'utilisation |
| EP3810085A1 (fr) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine |
| CN113015747A (zh) | 2018-10-19 | 2021-06-22 | 默克专利股份公司 | 用于治疗结肠直肠癌的阿比妥单抗 |
| KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
| CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN114366749B (zh) * | 2020-10-15 | 2023-06-30 | 中国人民解放军海军军医大学 | 整合素抑制剂在制备治疗肾癌的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2204890T3 (es) | 1991-03-06 | 2004-05-01 | Merck Patent Gmbh | Anticuerpos monoclonales humanizados. |
| DE69531187T2 (de) | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
| JP3461945B2 (ja) | 1994-12-26 | 2003-10-27 | 株式会社日本製鋼所 | 高低圧一体型タービンロータの製造方法 |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| DE69833755T2 (de) * | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| JP2002534959A (ja) | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | 免疫原性タンパク質の改変方法 |
| WO2002069232A2 (fr) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Procede d'identification d'epitopes de lymphocytes t et utilisation dans la preparation de molecules a immunogenicite reduite |
| NZ540562A (en) * | 2002-11-26 | 2008-04-30 | Pdl Biopharma Inc | Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| KR20060002667A (ko) | 2004-07-03 | 2006-01-09 | 삼성전자주식회사 | 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브 |
| ATE509954T1 (de) * | 2005-12-30 | 2011-06-15 | Merck Patent Gmbh | Anti-cd19-antikörper mit reduzierter immunogenität |
| US7669429B2 (en) | 2006-01-19 | 2010-03-02 | Bassler Sr G Scott | Rapid food chiller |
-
2008
- 2008-07-17 JP JP2010516422A patent/JP5341889B2/ja active Active
- 2008-07-17 EP EP12004296A patent/EP2526967A1/fr not_active Withdrawn
- 2008-07-17 CN CN200880024003.1A patent/CN101687039B/zh active Active
- 2008-07-17 CA CA2693863A patent/CA2693863C/fr active Active
- 2008-07-17 DK DK08784834.7T patent/DK2167128T3/da active
- 2008-07-17 AU AU2008277907A patent/AU2008277907B2/en active Active
- 2008-07-17 WO PCT/EP2008/005852 patent/WO2009010290A2/fr active Application Filing
- 2008-07-17 EA EA201070150A patent/EA019485B1/ru not_active IP Right Cessation
- 2008-07-17 EP EP08784834A patent/EP2167128B1/fr active Active
- 2008-07-17 KR KR1020107003397A patent/KR101559596B1/ko active IP Right Grant
- 2008-07-17 US US12/669,408 patent/US8562986B2/en active Active
- 2008-07-17 SI SI200830845T patent/SI2167128T1/sl unknown
- 2008-07-17 PT PT87848347T patent/PT2167128E/pt unknown
- 2008-07-17 ES ES08784834T patent/ES2395799T3/es active Active
- 2008-07-17 BR BRPI0815567A patent/BRPI0815567B8/pt active IP Right Grant
- 2008-07-17 PL PL08784834T patent/PL2167128T3/pl unknown
-
2010
- 2010-01-12 IL IL203269A patent/IL203269A/en active IP Right Grant
- 2010-02-16 ZA ZA2010/01124A patent/ZA201001124B/en unknown
- 2010-09-28 HK HK10109278.2A patent/HK1143523A1/xx unknown
-
2012
- 2012-11-21 HR HRP20120949AT patent/HRP20120949T1/hr unknown
- 2012-12-21 CY CY20121101248T patent/CY1113493T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8562986B2 (en) | 2013-10-22 |
| US20100254977A1 (en) | 2010-10-07 |
| HRP20120949T1 (en) | 2012-12-31 |
| JP5341889B2 (ja) | 2013-11-13 |
| SI2167128T1 (sl) | 2013-01-31 |
| PT2167128E (pt) | 2013-01-24 |
| WO2009010290A2 (fr) | 2009-01-22 |
| CN101687039B (zh) | 2014-04-16 |
| CN101687039A (zh) | 2010-03-31 |
| BRPI0815567B1 (pt) | 2019-06-04 |
| KR101559596B1 (ko) | 2015-10-12 |
| AU2008277907B2 (en) | 2013-08-22 |
| JP2010533480A (ja) | 2010-10-28 |
| ZA201001124B (en) | 2010-11-24 |
| BRPI0815567B8 (pt) | 2021-05-25 |
| EP2167128B1 (fr) | 2012-10-24 |
| AU2008277907A1 (en) | 2009-01-22 |
| EP2526967A1 (fr) | 2012-11-28 |
| PL2167128T3 (pl) | 2013-03-29 |
| ES2395799T3 (es) | 2013-02-15 |
| CA2693863C (fr) | 2017-10-03 |
| EA019485B1 (ru) | 2014-04-30 |
| IL203269A (en) | 2014-11-30 |
| KR20100057010A (ko) | 2010-05-28 |
| DK2167128T3 (da) | 2012-12-03 |
| EA201070150A1 (ru) | 2010-08-30 |
| CY1113493T1 (el) | 2016-06-22 |
| EP2167128A2 (fr) | 2010-03-31 |
| CA2693863A1 (fr) | 2009-01-22 |
| WO2009010290A3 (fr) | 2009-04-09 |
| BRPI0815567A2 (pt) | 2015-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120949T1 (en) | Engineered anti-alpha v- integrin hybrid antibodies | |
| HRP20182174T1 (hr) | Anti-il-23p19 antitijela proizvedena genetičkim inženjeringom | |
| IL200581A0 (en) | Engineered anti-il-23r antibodies | |
| GB0708002D0 (en) | Antibodies | |
| EP2142214A4 (fr) | Anticorps anti-ige | |
| SI2200700T1 (sl) | Nova protitelesa | |
| IL198424A0 (en) | Hybrid immunoglobulins with moving parts | |
| GB0821100D0 (en) | Antibodies | |
| EP2138576A4 (fr) | Anticorps anti-claudine-4 | |
| EP2337798A4 (fr) | Anticorps spécifiques de l'asb | |
| IL201552A0 (en) | Antibodies against il-25 | |
| GB0718737D0 (en) | Antibodies | |
| GB0702888D0 (en) | Novel Antibodies | |
| EP2160407A4 (fr) | Anticorps neutralisants | |
| HK1153502A1 (en) | Anti-bst2 antibody bst2 | |
| ZA201006099B (en) | Anti-tyrp1 antibodies | |
| EP2274332A4 (fr) | Anticorps anti-tnf alpha | |
| ZA201007976B (en) | Anti-pirb antibodies | |
| EP2217626A4 (fr) | Epitope pour la neutralisation d'anticorps | |
| GB0818356D0 (en) | Antibodies | |
| GB0724185D0 (en) | Antibodies | |
| GB0823562D0 (en) | Antibodies |